2. Search Result
Search Result
Isoforms Recommended: PARP7
Results for "

PARP7

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Recombinant Proteins

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155351
    PARP7-IN-15

    		PARP Cancer
    PARP7-IN-15 (Compound 18) is a PARP7 inhibitor with IC50 of 0.56 nM, that has antitumor activity .
    PARP7-IN-15
  • HY-163081
    PARP7-IN-17

    		PARP Cancer
    PARP7-IN-17 is a potent inhibitor of PARP7 with IC50 of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .
    PARP7-IN-17
  • HY-163719
    PARP7-IN-22

    		PARP Cancer
    PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC50 of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .
    PARP7-IN-22
  • HY-163492
    PARP7-IN-19

    		PARP Cancer
    PARP7-IN-19 (compound 5a) is an inhibitor of PARP7 ( IC50 ≤10nM). PARP7-IN-19 can be used in the research area of tumors .
    PARP7-IN-19
  • HY-D1188
    PARP7-probe-1

    		PARP Cancer
    PARP7-probe-1 is a chemiluminescent labeled PARP7 probe. PARP7-probe-1 is a biotinylated probe binding to the PARP7 active site. PARP7-probe-1 can be used for the research of PARP7 function .
    PARP7-probe-1
  • HY-151609
    PARP7-IN-12

    		PARP Cancer
    PARP7-IN-12 is a potent PARP7 Inhibitor with an IC50 value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .
    PARP7-IN-12
  • HY-162172
    PARP7-IN-18

    		PARP Cancer
    Parp7-in-18 (Compund 8) is a selective PARP7 inhibitor with an IC50 of 0.11 nM. PARP7-IN-18 exhibits good anticancer activity and pharmacokinetic properties .
    PARP7-IN-18
  • HY-161607
    PARP7-IN-21

    		PARP Cancer
    PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC50 of ＜ 10 nM .
    PARP7-IN-21
  • HY-173259
    PARP7-IN-23

    		PARP Cancer
    PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells. PARP7-IN-23 has the potential for cancer research .
    PARP7-IN-23
  • HY-173262
    PARP7-IN-24

    		PARP Cancer
    PARP7-IN-24 (compound 44) is a potent PARP7 inhibitor with an EC50 of 0.375 nM for pSTAT1 in NCI-H1373 cells. PARP7-IN-24 has the potential for cancer research .
    PARP7-IN-24
  • HY-156419A
    PARP7-IN-16 free base

    		PARP Cancer
    PARP7-IN-16 free base is the free base form of PARP7-IN-16 (HY-156419). PARP7-IN-16 free base is a selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .
    PARP7-IN-16 free base
  • HY-162349
    PARP7/HDACs-IN-1

    		HDAC PARP Cancer
    PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting PARP7/HDAC with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC50s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .
    PARP7/HDACs-IN-1
  • HY-156419
    PARP7-IN-16

    		PARP Cancer
    PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .
    PARP7-IN-16
  • HY-136174
    RBN-2397
    10+ Cited Publications

    		 PARP Cancer
    RBN-2397 is a potent, accross species and orally active NAD + competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .
    RBN-2397
  • HY-137770
    RBN010860

    		PARP Cancer
    RBN010860 (example 150) is a potent PARP7 inhibitor with an IC50 of <0.1 μM. RBN010860 can be used for the study of cancer .
    RBN010860
  • HY-148566
    OUL232

    		PARP Cancer
    OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. OUL232 is the most potent PARP10 inhibitor described to date (IC50=7.8 nM), as well as the first PARP12 inhibitor ever reported .
    OUL232
  • HY-178032
    PARP1-IN-44

    		PARP Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis STING Cancer
    PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active PARP1 inhibitor (IC50 = 0.6 nM), and also inhibits PARP2 (IC50 = 1.0 nM) and PARP7 (IC50 = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy .
    PARP1-IN-44
  • HY-162644
    Antitumor agent-170

    		PD-1/PD-L1 PARP Cancer
    Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .
    Antitumor agent-170
  • HY-162643
    Antitumor agent-169

    		PD-1/PD-L1 PARP Cancer
    Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC50s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with Ki of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .
    Antitumor agent-169
  • HY-RS14547
    Tiparp Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) PARP Others

    Tiparp Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tiparp gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tiparp Mouse Pre-designed siRNA Set A
    Tiparp Mouse Pre-designed siRNA Set A
  • HY-RS14546
    TIPARP Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) PARP Others

    TIPARP Human Pre-designed siRNA Set A contains three designed siRNAs for TIPARP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TIPARP Human Pre-designed siRNA Set A
    TIPARP Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: